PharmaCyte Biotech
PMCB
PMCB
32 hedge funds and large institutions have $2.35M invested in PharmaCyte Biotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.39% less ownership
Funds ownership: 13.02% → 12.63% (-0.39%)
2% less capital invested
Capital invested by funds: $2.4M → $2.35M (-$51.9K)
Holders
32
Holding in Top 10
–
Calls
$18K
Puts
$13K
Top Buyers
| 1 | +$99.2K | |
| 2 | +$47.6K | |
| 3 | +$32.1K | |
| 4 |
Renaissance Technologies
New York
|
+$11.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.21K |
Top Sellers
| 1 | -$31.9K | |
| 2 | -$28K | |
| 3 | -$27.7K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$14.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.5K |